Guidelines and policies for medical writers in the biotech industry: An update on the controversy

Biotechnology Annual Review

Volumn 10, Issue SPEC. ISS., 2004, Pages 259-264

  Foote, MaryAnn ^a  

^a AMGEN INC   (United States)

Author keywords

Biotechnology medical biotechnology; Clinical research publication of trials; Good publication practices; PhRMA guidelines; Uniform requirements for biomedical journals

Indexed keywords

BIOTECHNOLOGY; CLINICAL RESEARCH; CLINICAL STUDY; DOCUMENTATION; INDUSTRY; MARKETING; POLICY; PRACTICE GUIDELINE; REVIEW; WRITING;

EID: 7044264894     PISSN: 13872656     EISSN: None     Source Type: Book Series    
DOI: 10.1016/S1387-2656(04)10010-0     Document Type: Article

References (21)

1. Foote MA Review of current authorship guidelines and the controversy regarding publication of clinical trial data Biotech Ann Rev 9 2003 303-313
2. International Committee of Medical Journal Editors. Uniform requirements for manuscripts submitted to biomedical journals. N Engl J Med 1997;336:309-315
3. Bhopal R Rankin J McColl E et al. The vexed question of authorship: views of researchers in a British medical faculty BMJ 314 1997 1009-1012
4. Goodman NW Survey of fulfillment of criteria for authorship in published medical research BMJ 309 1994 1482
5. Davidoff F DeAngelis CD Drazen JM et al. Sponsorship, authorship, and accountability Ann Intern Med 135 2001 463-466
6. Griffin J Clinical trial data: Ownership, access and publication Clin Res 2 2002 12-22
7. Hirsch LJ Conflicts of interest in drug development: The practices of Merck - Co., Inc Sci Engineer Ethics 8 2002 429-442
8. Food and Drug Administration. Regulation of drug-company-sponsored activities in scientific or educational contexts (draft proposed policy, October 8, 1991). Division of Drug Marketing, Advertising, and Communications (HFD-240), Rockville, Maryland
9. Food and Drug Administration. Guidance for industry: Industry-supported scientific and educational activities published by FDA. Federal Register 1997;62:64073-64100
10. Altman LK Some authors in medical journals may get paid by "spin doctors" The New York Times C3 October 4, 1994
11. Brennan TA Buying editorials N Engl J Med 331 1994 673-675
12. Rennie D Flanagin A Authorship! Authorship! Guests, ghosts, grafters, and the two-sided coin JAMA 271 1994 469-471
13. DeBakey L DeBakey S Ghostwriters: Not always what they appear JAMA 274 1995 870-871
14. Flanagan A Rennie D Acknowledging ghosts JAMA 273 1995 73
15. Levy D Ghostwriters: A hidden resource for drug makers USA Today 1A September 25, 1996 2A
16. Reidenberg JW Unmasking ghost writers Clin. Pharmacol. Ther 70 2001 208-209
17. Hamilton CW Royer MG for the AMWA 2002 Task Force on the Contributions of Medical Writers to Scientific Publications. AMWA Position Statement on the Contributions of Medical Writers to Scientific Publications AMWA J 18 2003 13-16
18. American Medical Writers Association. Code of Ethics. http://www.amwa.org/about/ethics (assessed 28 May 2003)
19. International Conference on Harmonisation, Guidance for Industry, E6 Good Clinical Practice: Consolidated Guidance, April 1996, http://www.ifpma.org/pdfifpma/e6.pdf (accessed 28 May 2003)
20. Pharmaceutical Research and Manufacturers of America. PhRMA adopts principles for conduct of clinical trials and communication of clinical trial results. http://www.phrma.org/mediaroom/press/releases/20.06.2002.427.cfm (accessed 28 May 2003)
21. Wager E Field EA Grossman L Good publication practice for pharmaceutical companies Curr Med Res Opin 19 2003 149-154